Cytotoxicity of σ-receptor ligands is associated with major changes of cellular metabolism and complete occupancy of the σ-2 subpopulation

Journal of Nuclear Medicine

Volumn 49, Issue 12, 2008, Pages 2049-2056

  Rybczynska, Anna A ^a   Dierckx, Rudi A ^a   Ishiwata, Kiichi ^b   Elsinga, Philip H ^a   Van Waarde, Aren ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

Author keywords

receptor occupancy; 11C choline; 11C methionine; 18F FDG; 18F FLT; Cellular proliferation; Glioma cells; PET

Indexed keywords

1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE; 1 (3,4 DIMETHOXYPHENETHYL) 4 (3 PHENYLPROPYL)PIPERAZINE C 11; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; HALOPERIDOL; LIGAND; METHIONINE C 11; PENTAZOCINE; RIMCAZOLE; TRACER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL COUNT; CELL METABOLISM; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG BINDING; DRUG UPTAKE; IC 50; IN VITRO STUDY; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR OCCUPANCY;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GLIOMA; LETHAL DOSE 50; RATS; RECEPTORS, SIGMA;

EID: 57149120547     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.053876     Document Type: Article

References (39)

1. Su TP. Sigma receptors: putative links between nervous, endocrine and immune systems. Eur J Biochem. 1991;200:633-642.
2. Quirion R, Chicheportiche R, Contreras PC, et al. Classification and nomenclature of phencyclidine and sigma binding receptor sites. Trends Neurosci. 1987;10:444-446.
3. 1 receptor ligand. Expert Opin Ther Targets. 2008;12:45-58.
4. Hellewell SB, Bruce A, Feinstein G, Orringer J, Williams W, Bowen WD. Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. Eur J Pharmacol. 1994;268:9-18.
5. Aydar E, Onganer P, Perrett R, Djamgoz MB, Palmer CP. The expression and functional characterization of sigma σ1 receptors in breast cancer cell lines. Cancer Lett. 2006;242:245-257.
6. Vilner BJ, John CS, Bowen WD. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995;55:408-413.
7. Thomas GE, Szucs M, Mamone JY, et al. Sigma and opioid receptors in human brain tumors. Life Sci. 1990;46:1279-1286.
8. Kekuda R, Prasad PD, Fei YJ, Leibach FH, Ganapathy V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem Biophys Res Commun. 1996;229:553-558.
9. Mei JF, Pasternak GW. Molecular cloning and pharmacological characterization of the rat sigma1 receptor. Biochem Pharmacol. 2001;62:349-355.
10. Guitart X, Codony X, Monroy X. Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl). 2004;174:301-319.
11. Newman AH, Coop A. Medicinal chemistry: new chemical classes and subtype-selective ligands. In: Matsumoto RR, Bowen WD, Su TP, eds. Sigma Receptors: Chemistry, Cell Biology and Clinical Implications. Berlin, Germany: Springer Verlag; 2007:25-44.
12. Vilner BJ, de Costa BR, Bowen WD. Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci. 1995;15:117-134.
13. Brent PJ, Pang GT. Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol. 1995;278:151-160.
14. Brent PJ, Pang G, Little G, Dosen PJ, Van Helden DF. The sigma receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular-free calcium levels [Ca2+]i in colon and mammary adenocarcinoma cells. Biochem Biophys Res Commun. 1996;219:219-226.
15. 1 antagonists in tumour cell lines. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:106-113.
16. Nordenberg J, Perlmutter I, Lavie G, et al. Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. Int J Oncol. 2005;27:1097-1103.
17. Moody TW, Leyton J, John C. Sigma ligands inhibit the growth of small cell lung cancer cells. Life Sci. 2000;66:1979-1986.
18. Spruce BA, Campbell LA, McTavish N, et al. Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004;64:4875-4886.
19. 1 receptors. Nucl Med Biol. 2000;27:255-261.
20. Ferris RM, Harfenist M, McKenzie GM, Cooper B, Soroko FE, Maxwell RA. BW 234U, (cis-9-(3,5-dimethyl-1-piperazinyl)propyl]carbazole dihydrochloride): a novel antipsychotic agent. J Pharm Pharmacol. 1982;34:388-390.
21. 3H](+)-pentazocine binding to rat brain sigma 1 receptors. Eur J Pharmacol. 1994;266:131-138.
22. Maeda DY, Williams W, Bowen WD, Coop A. A sigma-1 receptor selective analogue of BD1008: a potential substitute for (+)-opioids in sigma receptor binding assays. Bioorg Med Chem Lett. 2000;10:17-18.
23. 11C]SA4503. Nucl Med Biol. 2006;33:543-548.
24. Van Waarde A, Been LB, Ishiwata K, Dierckx RA, Elsinga PH. Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells. J Nucl Med. 2006;47:1538-1545.
25. Van Waarde A, Jager PL, Ishiwata K, Dierckx RA, Elsinga PH. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation. J Nucl Med. 2006;47:150-154.
26. 18F-labeled 1-[2-(4-alkoxy-3-methoxyphenyl)ethyl] -4-(3-phenylpropyl)piperazines as sigma receptor ligands for positron emission tomography studies. Nucl Med Biol. 2003;30:273-284.
27. Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, Mita S. Binding properties of SA4503, a novel and selective sigma 1 receptor agonist. Eur J Pharmacol. 1996;306:271-279.
28. 2 receptor binding affinity and selectivity of SA4503 and fluoroethyl SA4503. Synapse. 2006;59:350-358.
29. Slosman DO, Pugin J. Lack of correlation between tritiated deoxyglucose, thallium-201 and technetium-99m-MIBI cell incorporation under various cell stresses. J Nucl Med. 1994;35:120-126.
30. Furuta M, Hasegawa M, Hayakawa K, et al. Rapid rise in FDG uptake in an irradiated human tumour xenograft. Eur J Nucl Med. 1997;24:435-438.
31. Clavo AC, Wahl RL. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells. J Nucl Med. 1996;37:502-506.
32. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217.
33. 18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging. 2005;32:257-263.
34. Yoshimoto M, Waki A, Obata A, Furukawa T, Yonekura Y, Fujibayashi Y. Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl Med Biol. 2004;31:859-865.
35. Vaalburg W, Coenen HH, Crouzel C, et al. Amino acids for the measurement of protein synthesis in vivo by PET. Int J Rad Appl Instrum B. 1992;19:227-237.
36. Crawford KW, Bowen WD. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002;62:313-322.
37. 1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. Mol Cancer Ther. 2006;5:1807-1816.
38. Choi S-R, Yang B, Plössl K, et al. Development of a Tc-99m labeled sigma-2 receptor-specific ligand as a potential breast tumor imaging agent. Nucl Med Biol. 2001;28:657-666.
39. 3H]haloperidol in human and rat cerebellum. Naunyn Schmiedebergs Arch Pharmacol. 1992;345:197-202.